Rifaximin Should NOT Be Used for Prevention of Recurrent Diverticulitis
Do not prescribe rifaximin as adjunct therapy to prevent recurrence of uncomplicated diverticulitis. The highest-quality guideline evidence explicitly recommends against this practice 1.
Guideline Recommendations
The 2021 AGA Clinical Practice Update provides clear guidance: patients with a history of diverticulitis should not be treated with rifaximin to prevent recurrent diverticulitis 1. This recommendation is based on insufficient evidence supporting cyclic rifaximin use for this indication. The 2022 American College of Physicians guideline similarly does not endorse rifaximin for diverticulitis prevention 2.
The most recent 2025 Fiesole Consensus (32 international experts from 14 countries) acknowledges that rifaximin may help relieve symptoms in symptomatic uncomplicated diverticular disease but does not recommend it for preventing acute diverticulitis recurrence 3.
Why This Matters
The evidence base is fundamentally weak:
Meta-analyses show minimal benefit: A 2023 systematic review found only a 24% risk reduction for secondary prevention, but with very low-quality evidence (I² = 92% heterogeneity) and an NNT of just 5—suggesting the data is unreliable 4
No FDA approval: Rifaximin is FDA-approved only for travelers' diarrhea, hepatic encephalopathy, and IBS-D—not diverticular disease 5
Cost-effectiveness concerns: Multiple reviews note that the cost-benefit ratio for long-term rifaximin treatment remains undetermined and appears unfavorable 6, 7, 8
What Actually Works
Instead of rifaximin, counsel patients on evidence-based prevention strategies 1:
- High-fiber diet from fruits, vegetables, whole grains, and legumes (not just supplements)
- Maintain normal BMI and avoid weight gain
- Regular vigorous physical activity
- Smoking cessation
- Avoid NSAIDs, opiates, and corticosteroids when possible
Common Pitfalls
Don't confuse symptomatic uncomplicated diverticular disease (SUDD) with diverticulitis prevention. Some Italian studies suggest rifaximin may help with chronic abdominal symptoms in SUDD 7, 9, but this is a different clinical entity than preventing acute inflammatory episodes. The 2017 Italian Society of Gastroenterology position paper explicitly states there is "no evidence available on the efficacy of rifaximin treatment on acute uncomplicated diverticulitis" 7.
Don't be swayed by older meta-analyses. A 2011 meta-analysis showed promise 9, but subsequent larger trials failed to confirm benefit, leading to the current guideline recommendations against use 1.
The Bottom Line
While rifaximin is safe and well-tolerated, there is no role for it in preventing recurrent diverticulitis based on current high-quality guideline evidence. Focus instead on lifestyle modifications that have proven benefit for reducing recurrence risk.